Market Trends of Global Single-use Bioreactor Industry
This section covers the major market trends shaping the Single-use Bioreactor Market according to our research experts:
Monoclonal Antibodies Segment is Anticipated to Witness Growth
The main advantage of using monoclonal antibodies (MAbs) in treating several diseases (such as lymphoma and leukemia, as well as autoimmune diseases) is that they are taken from a biological source and can produce antibodies in the long term. While the use of disposables (single-use bioreactors) eliminates cleaning and sterilization steps, as well as cleaning validation, it reduces cost and the time of operation per batch. Thus, with the increasing demand for MAbs manufacturing, the application of Single Use Bioreactor technology (SUBs) for the production and manufacturing of MAb is also increasing. Hence, it is expected to drive the growth of the segment.
An increase in research and development (R&D) activities, collaborations, and strategic partnerships along with soaring demand for new vaccines and therapeutics and rising chronic and infectious diseases is expected to boost the segment growth. For instance, in January 2022, HaemaLogiX Ltd (HaemaLogiX) and Lonza entered into an agreement to manufacture the next clinical batch (cGMP) of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab, a monoclonal antibody that binds to a cell surface target called kappa myeloma antigen (KMA) that is only found on myeloma cancer cells and not on normal plasma cells. Such strategies for the development of monoclonal antibodies are anticipated to create demand for SUBs and Single Use Technology in manufacturing facilities, thereby expected to drive segment growth.
Moreover, an article published by 53Biologics in July 2022 stated that monoclonal antibody biotherapeutics account for roughly 1/5th of new drug approvals by the Food and Drug Administration (FDA) every year, and Bioprocessing Equipment such as SUBs can improve efficiency and performance in MAb manufacturing. Thus, the improved efficiency and performance of SUBs in manufacturing of MAb are expected to boost the segment growth.
Therefore, owing to the factors mentioned above, the segment is anticipated to witness growth over the forecast period.
North America Dominates the Market and is Expected to do so during the Forecast Period
North America is expected to be a dominant region in the Single Use Bioreactor Market due to increasing chronic illnesses coupled with the emerging need for developing new drugs.
More than 34.2 million Americans have diabetes, and more than 868,000 people die from heart disease each year, according to data from the Centers for Disease Control and Prevention that was published on January 10th, 2022. In addition to this, the data updated by the Food and Drug Administration (FDA) in 'Fact Sheet: FDA at a Glance' published in November 2021 shows that there are 4,944 FDA-Registered Facilities for the development of biologics and 6,799 for human drugs. Such a high number of manufacturing facilities to produce drugs is expected to create opportunities for the use of SUBs, thereby expected to drive market growth in the region.
Furthermore, the pharmaceutical and biopharmaceutical industries' innovative drug development, utilizing Bioprocess Containers and single-use bioreactors, is anticipated to fuel market expansion in this sector. About 382 vaccine candidates were under development as of February 2021, according to the International Federation of Pharmaceutical Manufacturers and Associations' "Facts & Figures Report 2021," of which 24 were in Phase I, 34 were in Phase II, and 23 were in Phase III trials. The biopharmaceutical sector is taking extraordinary, quick steps to get vaccinations to patients. Thus, such increasing demand for the development of biologics in the country is expected to create demand for the use of single-use bioreactors over the forecast period.
Moreover, the developments and product launches are also expected to drive market growth in the country. For instance, in October 2021, the Agilitech bioreactor controller was launched by Agilitech, one of the Bioreactor Manufacturers USA, a United States-based company that provides simultaneous control of up to two single-use bioreactors from 30 L up to 2000 L. The design of the product allows for integration with any Bioreactor Brands of single-use bioreactor. Such developments in the pharmaceutical and biopharmaceutical businesses are driving market expansion and are anticipated to favorably affect the growth of the studied market in the country during the projected year.
